RxDoctor Payments Data

Zbigniew Woznica, MD

Internal Medicine · Hartford, CTNPI 1174536486

Payments from drug & device makers

$3,245in general payments, 2019–2025

Across 86 payments — averaging $37.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$713
  • Amgen$631
  • Novo Nordisk$562
  • AbbVie$369
  • Pfizer$164
  • Novartis$164
  • plus $642 from 10 others

What the payments were for

  • Food & beverage$3,238100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,153
Medicare patients
106
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$75,888
JardianceEmpagliflozin49$74,927
JanuviaSitagliptin Phosphate50$69,764
OzempicSemaglutide32$41,744
TrulicityDulaglutide27$36,178
TradjentaLinagliptin32$35,145
Tresiba Flextouch U-100Insulin Degludec31$22,070
MounjaroTirzepatide11$18,797
FarxigaDapagliflozin Propanediol12$18,395
JanumetSitagliptin Phos/Metformin Hcl13$10,763
LivaloPitavastatin Calcium12$9,957
VascepaIcosapent Ethyl15$9,582
CrestorRosuvastatin Calcium12$8,944
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$6,398
SynthroidLevothyroxine Sodium39$4,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$20$110,07381 claims
MerckJanuvia, Janumet$58$80,52763 claims
PfizerEliquis$164$75,88873 claims
Lilly USA, LLCTrulicity, Mounjaro$95$54,97538 claims
Novo NordiskOzempic$562$41,74432 claims
AstraZenecaFarxiga, Crestor$71$27,33924 claims
Kowa Pharmaceuticals America, Inc.Livalo$43$9,95712 claims
AbbVieSynthroid$369$4,71439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →